BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8421089)

  • 1. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
    Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
    J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
    Nasr C; Mason A; Mayberg M; Staugaitis SM; Asa SL
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4776-80. PubMed ID: 16968791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid.
    Ezzat S; Asa SL; Stefaneanu L; Whittom R; Smyth HS; Horvath E; Kovacs K; Frohman LA
    J Clin Endocrinol Metab; 1994 Mar; 78(3):555-60. PubMed ID: 8126126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal and growth hormone (GH)-secreting adenomatous human pituitaries release somatostatin and GH-releasing hormone.
    Joubert D; Benlot C; Lagoguey A; Garnier P; Brandi AM; Gautron JP; Legrand JC; Peillon F
    J Clin Endocrinol Metab; 1989 Mar; 68(3):572-7. PubMed ID: 2493037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome.
    Cuttler L; Jackson JA; Saeed uz-Zafar M; Levitsky LL; Mellinger RC; Frohman LA
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1148-54. PubMed ID: 2498385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A growth hormone-releasing hormone-producing pancreatic islet cell tumor metastasized to the pituitary is associated with pituitary somatotroph hyperplasia and acromegaly.
    Sanno N; Teramoto A; Osamura RY; Genka S; Katakami H; Jin L; Lloyd RV; Kovacs K
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2731-7. PubMed ID: 9253362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
    Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
    Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammosomatotroph adenoma causing gigantism in an 8-year old boy: a possible pathogenetic mechanism.
    Dubuis JM; Deal CL; Drews RT; Goodyer CG; Lagacé G; Asa SL; Van Vliet G; Collu R
    Clin Endocrinol (Oxf); 1995 May; 42(5):539-49. PubMed ID: 7621575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary pituitary hyperplasia with infantile gigantism.
    Gläsker S; Vortmeyer AO; Lafferty AR; Hofman PL; Li J; Weil RJ; Zhuang Z; Oldfield EH
    J Clin Endocrinol Metab; 2011 Dec; 96(12):E2078-87. PubMed ID: 21976722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
    Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of desensitization of adenomatous somatotrophs to growth-hormone releasing hormone in acromegaly.
    Spada A; Elahi FR; Arosio M; Sartorio A; Guglielmino L; Vallar L; Faglia G
    J Clin Endocrinol Metab; 1987 Mar; 64(3):585-91. PubMed ID: 3102543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism.
    Maghnie M; Salati B; Bianchi S; Rallo M; Tinelli C; Autelli M; Aimaretti G; Ghigo E
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1574-9. PubMed ID: 11297586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line.
    Asa SL; Kovacs K; Horvath E; Singer W; Smyth HS
    J Clin Endocrinol Metab; 1992 Jul; 75(1):68-75. PubMed ID: 1352308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary tumour causing gigantism. Morphology and in vitro hormone secretion.
    Anniko M; Ritzén EM
    ORL J Otorhinolaryngol Relat Spec; 1986; 48(3):180-90. PubMed ID: 3714202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergence between growth hormone responses to insulin-induced hypoglycaemia and growth hormone-releasing hormone in patients with non-functioning pituitary macroadenomas and hyperprolactinaemia.
    Beentjes JA; Tjeerdsma G; Sluiter WJ; Dullaart RP
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):391-8. PubMed ID: 8959076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GHRH excess and blockade in X-LAG syndrome.
    Daly AF; Lysy PA; Desfilles C; Rostomyan L; Mohamed A; Caberg JH; Raverot V; Castermans E; Marbaix E; Maiter D; Brunelle C; Trivellin G; Stratakis CA; Bours V; Raftopoulos C; Beauloye V; Barlier A; Beckers A
    Endocr Relat Cancer; 2016 Mar; 23(3):161-70. PubMed ID: 26671997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion.
    Lefebvre S; De Paepe L; Abs R; Rahier J; Selvais P; Maiter D
    Eur J Endocrinol; 1995 Sep; 133(3):320-4. PubMed ID: 7581949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling.
    Kineman RD; Teixeira LT; Amargo GV; Coschigano KT; Kopchick JJ; Frohman LA
    Endocrinology; 2001 Sep; 142(9):3764-73. PubMed ID: 11517152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia: a pseudotumoral disease.
    Peillon F; Dupuy M; Li JY; Kujas M; Vincens M; Mowszowicz I; Derome P
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1008-15. PubMed ID: 1939514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.